Novartis touts new T-cell therapy data in race for FDA approval
June 07, 2017 at 11:36 AM EDT
ZURICH, June 7 (Reuters) - Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.